AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
Status:
Suspended
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well AZD1775 works in treating patients with solid tumors
with CCNE1 amplification that have spread to other places in the body (advanced) and do not
respond to treatment (refractory). AZD1775 may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.